I'm LongbridgeAI, I can summarize articles.CSPC PHARMA (01093.HK) -0.225 (-2.852%) Short selling $203.82M; Ratio 36.092% announced its results for the first three quarters ended September 2026. Revenue amounted to RMB25.26 billion, up 27% YoY. Net profit rose 101.5% YoY to RMB7.076 billion, with EPS at RMB0.6214. Excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation expenses, underlying profit for the first three quarters amounted to RMB7.22 billion, up 134.5% YoY.
During the period, R&D expenses amounted to RMB4.643 billion, representing an increase of 10.9% compared with the same period last year, accounting for approximately 30.2% of finished drug business revenue.
Since the beginning of the year, the group's registration and approval progress in China included approval for the launch of seven new products; acceptance of marketing applications for 10 products; five breakthrough therapy designations granted; and 32 clinical trial approvals obtained. In overseas markets, the group also obtained 12 clinical trial approvals and one fast-track designation, while securing marketing approval in the European Union for one self-developed drug.(sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)
AASTOCKS Financial News
